Molecular portraits of human breast tumours von Botstein, David, Perou, Charles M, Sørlie, Therese, Eisen, Michael B, van de Rijn, Matt, Jeffrey, Stefanie S, Rees, Christian A, Pollack, Jonathan R, Ross, Douglas T, Johnsen, Hilde, Akslen, Lars A, Fluge, Øystein, Pergamenschikov, Alexander, Williams, Cheryl, Zhu, Shirley X, Lønning, Per E, Børresen-Dale, Anne-Lise, Brown, Patrick O

Volltext

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer von Eikesdal, H.P., Yndestad, S., Elzawahry, A., Llop-Guevara, A., Gilje, B., Blix, E.S., Espelid, H., Lundgren, S., Geisler, J., Vagstad, G., Venizelos, A., Minsaas, L., Leirvaag, B., Gudlaugsson, E.G., Vintermyr, O.K., Aase, H.S., Aas, T., Balmaña, J., Serra, V., Janssen, E.A.M., Knappskog, S., Lønning, P.E.

Volltext

Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding? von Lønning, P.E., Geisler, J.

Volltext

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers von Lønning, P E, Knappskog, S

Volltext

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum von Lønning, P.E.

Volltext

Patterns of genomic evolution in advanced melanoma von Birkeland, E., Zhang, S., Poduval, D., Geisler, J., Nakken, S., Vodak, D., Meza-Zepeda, L. A., Hovig, E., Myklebost, O., Knappskog, S., Lønning, P. E.

Volltext

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, or in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer von GEISLER, J, KING, N, DOWSETT, M, OTTESTAD, L, LUNDGREN, S, WALTON, P, KORMESET, P. O, LØNNING, P. E

Volltext

Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for... von Lønning, P.E.

Volltext

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients von Aas, Turid, Børresen, Anne-Lise, Geisler, Stephanie, Smith-Sørensen, Birgitte, Johnsen, Hilde, Varhaug, Jan E, Akslen, Lars A, Lønning, Per E

Volltext

Aromatase inhibitors in breast cancer von L√∏nning, P E

Volltext

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy von LØNNING, Per E, TAYLOR, Paul D, ANKER, Gun, IDDON, Julie, LIV WIE, JØRGENSEN, Linn-Marie, MELLA, Olav, HOWELL, Anthony

Volltext

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? von Lønning, P.E

Volltext

Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study von JOHANNESSEN, D. C, ENGAN, T, DI SALLE, E, ZURLO, M. G, PAOLINI, J, ORNATI, G, PISCITELLI, G, KVINNSLAND, S, LØNNING, P. E

Volltext

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis von Norum, J., Olsen, J. A., Wist, E. A., Lønning, P. E.

Volltext

Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors von Pollack, Jonathan R., Sørlie, Therese, Perou, Charles M., Rees, Christian A., Jeffrey, Stefanie S., Lonning, Per E., Tibshirani, Robert, Botstein, David, Børresen-Dale, Anne-Lise, Brown, Patrick O.

Volltext

The progenitor cell marker NG2 MPG promotes chemoresistance by activation of integrin-dependent PI3K Akt signaling von Chekenya, M, Krakstad, C, Svendsen, A, Netland, I A, Staalesen, V, Tysnes, B B, Selheim, F, Wang, J, Sakariassen, P Ø, Sandal, T, Lønning, P E, Flatmark, T, Enger, P Ø, Bjerkvig, R, Sioud, M, Stallcup, W B

Volltext

CYP17 and breast cancer risk : The polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1 von KRISTENSEN, V. N, HARALDSEN, E. K, ANDERSON, K. B, LØNNING, P. E, ERIKSTEIN, B, KARESEN, R, GABRIELSEN, O. S, BØRRESEN-DALE, A.-L

Volltext

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients von GEISLER, J, KING, N, ANKER, G, ORNATI, G, DI SALLE, E, LØNNING, P. E, DOWSETT, M

Volltext

Breast cancer prognostication and prediction: are we making progress? von Lønning, P. E.

Volltext

Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique von Monstad, S. E., Storstein, A., Dørum, A., Knudsen, A., Lønning, P. E., Salvesen, H. B., Aarseth, J. H., Vedeler, C. A.

Volltext